Icecure Medical Ltd. (ICCM) has released an update.
IceCure Medical Ltd. reports successful results from a Japanese study indicating no local breast cancer recurrence five years after treatment with their ProSense® cryoablation system. The study, published in the journal Breast Cancer, highlights excellent cosmetic outcomes, patient satisfaction, and improved quality of life. These findings support ProSense® as a potential non-surgical standard treatment for early-stage breast cancer, with regulatory clearance in Japan anticipated in the second half of 2024.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
